PHAXIAM Therapeutics S.A.
PHAXIAM Therapeutics S.A. (PHXM) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
phxm · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
PHAXIAM Therapeutics S.A.You PHXM | $20M | N/A | — | -$5.00 |
 AlphaTON Capital Corp. ATON | $1M | N/A | — | -$5.72 |
 COSCIENS Biopharma Inc. CSCI | $9M | N/A | — | -$5.93 |
 Dominari Holdings Inc. DOMH | $51M | N/A | — | -$1.57 |
 Elevation Oncology, Inc. ELEV | $22M | N/A | — | -$0.78 |
 Kineta, Inc. KA | $7M | N/A | — | -$1.42 |
 MEI Pharma, Inc. MEIP | $20M | N/A | — | -$2.39 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for PHAXIAM Therapeutics S.A. (PHXM) measures how much investors pay for each dollar of the company's trailing earnings. PHXM's current PE ratio of N/A is calculated by dividing its stock price of $3.10 by its TTM earnings per share of -$5.00.
Frequently asked questions
PHXM pe ratio · 6 questionsPHXM's current PE ratio is N/A as of 2026-06-09, based on a stock price of $3.10 and TTM EPS of -$5.00. Data sourced from Financial Modeling Prep via PHXM's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · PHAXIAM Therapeutics S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09